United Therapeutics Revenue, Profits - UTHR Quarterly Income Statement

Add to My Stocks
$125.86 $0.34 (0.27%) UTHR stock closing price Sep 19, 2018 (Closing)

Looking at financial statements, along with the United Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $444.5M for 2018 Q2 impacts the UTHR stock. Investors typically check year over year or quarter over quarter revenue growth. Revenue for year 2018 Q2 is $444.5M and has increased from $389.2M quarter on quarter as is evident when you compare the latest figures in the latest United Therapeutics profit and loss statement with those of the prior corresponding period. Also see United Therapeutics assets and United Therapeutics free cash flow for a complete valuation of UTHR stock.

View and download details of revenue and profits for United Therapeutics for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
United Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)61.7M53.2M53M19.5M18.9M14.3M28.4M23.6M20M-
United Therapeutics Gross Profit
Research & Development Expense82.3M35.7M113.6M55M59.8M36.2M66.9M45.9M35.2M-0.4M
Selling General & Admin Expense83.1M-6.6M159.1M47.2M277.4M56.4M139.5M100.1M72.2M5M
Income Before Depreciation Depletion Amortization217.4M306.9M139M323.8M88.5M263.6M174.2M238.6M285.2M363.7M
Depreciation Depletion Amortization----------
Non Operating Income3.4M4.7M5.5M--42.9M--0.5M1M1.1M-
Interest Expense2.9M2.6M3.5M3.3M1.4M-2.2M---
United Therapeutics Pretax Income
Provision for Income Taxes45M64.5M122M44.4M100.2M85M61.2M77.3M79.6M128.4M
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations172.9M244.5M19M276.3M-56M178.6M110.3M161.8M206.1M235.5M
Extraordinary Items & Discontinued Operations----------
United Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS43.4M43.9M43.8M44.1M44.9M45.9M45.4M46.2M46.9M48.7M
Average Shares used to compute Basic EPS43.1M43.3M43.2M43.4M44.9M44.5M42.2M43.2M44.3M45.4M
Income Before Nonrecurring Items172.9M244.5M90M276.3M-56M178.6M110.3M161.8M206.1M235.5M
Income from Nonrecurring Items---71M-------
United Therapeutics Earnings Per Share Basic Net
United Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items3.985.572.066.27-1.253.892.433.504.394.84
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on United Therapeutics stock analysis. It helps to look at the following income statement items:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $444.5M for this quarter of 2018 Q2. Our United Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $172.9M for United Therapeutics for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the UTHR income statement, one can check the United Therapeutics historical stock prices to check how the price has moved with time.

United Therapeutics Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
PS Ratio (price sales ratio)
Operating Margin
Net Profit Margin
Dividend Yield

Other Income Statements - United Therapeutics Corporation Industry Peers

Baxter International income statement, CORREVIO PHARMA income statement, Pfizer income statement